Sleep Quality & Psoriatic Arthritis
For people living with psoriatic arthritis (PsA), the comfort of a good night's sleep may feel out of reach for many.
Read more →What's hot
View all perspectives
What's Hot
Ultrasound in PsA
Dr. Arthur Kavanaugh discusses abstract 2206 presented at ACR22 in Philadelphia. Abstract 2206: Understanding Inter-rater Variability in Scoring of Entheseal Lesions: Results from the Diagnostic Ultrasound Enthesitis Tool (DUET) Study
Watch video →
Tapering TNFi in nonradiographic AxSpA
Dr. Peter Nash at ACR22 Convergence in Philadelphia, PA.
Watch video →
Sunday (Day 2): ACR 22 Daily Recap
ACR 2022 Daily Recap for Sunday, November 13th. Panelists: Drs. Robert Chao, Antoni Chan, Bella Mehta, Janet Pope, Yuz Yusof, Cassy Sims, Akhil Sood, Sheila Reyes and Jack Cush.
Watch video →
Spondyloarthritis: Novel Therapies, Diagnostic Dilemmas and Depression
Dr. Lianne Gensler discusses the following abstracts presented at ACR22 Convergence. Abstracts 1597, 1598, 1599 (treatment) and 1613, 1609 and 1614 (diagnosis and outcomes)
Watch video →
Deucravacitinib in PsA
Dr. Arthur Kavanaugh discusses abstract 1598 at ACR22 Convergence in Philadelphia. Abstract 1598: Safety and Efficacy of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Psoriatic Arthritis: 52-Week Results from a Randomized Phase 2 Trial
Watch video →
Sarilumab in Polymyalgia Rheumatica: Results from SAPHYR Trial
Dr. Michael Putman interviews Dr. Robert Speira about abstract 1676 presented at the ACR22 Convergence meeting in Philadelphia, PA. Abstract 1676: Sarilumab in Patients with Relapsing Polymyalgia Rheumatica: A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Trial (SAPHYR)
Watch video →
PET CT Imaging to Define Risk of Progression from PSO to PsA
Dr. Peter Nash discusses Abstract 1018 at ACR22 Convergence.
Watch video →
ACR22 Daily Recap: Saturday Recap
Panelists: Drs. Jack Cush, Michael Putman, Eric Dein, Patricia Harkins and Rachel Tate.
Watch video →
Bella Mehta bella_mehta
3 years 1 month ago
Year in review #ACR22
IV Tocilizumab FDA approved in GCA!!
Randomized trial of iv tocilizumab in PMR - 101 pts. Steroid taper was quicker.
https://t.co/BQT2H8LEFk
@rheumnow https://t.co/4KAYrz1IES
sheila RHEUMarampa
3 years 1 month ago
Very helpful slide on the different MOAs of JAK inhibitors (by Lui C et al.) shared by Dr. Langford
#ACR22 @RheumNow #RheumTwitter #yearinreview https://t.co/9VIOmzNoMq
Patients with RA are known to have a higher mortality risk than the general population.
In abstract 0246, Crowson et al propose a retrospective population-based study stratifying RA patients according to their comorbidities.
Max Konig MaxKonigMD
3 years 1 month ago
VEXAS is more common than you think in men >50 #ACR22 https://t.co/z2T6nBoI9a
Patricia Harkins DrTrishHarkins
3 years 1 month ago
Yr in review #ACR22 @RheumNow
🌟GLORIA 2 yr data:
👉Pred 5mg OD vs PBO >65y/o RA
✅⬇️ disease activity (DAS28 -0.38)
✅⬇️ joint damage (sharp/van der heijde -1.7)
❌ 24% ⬆️ a/e
“Weigh success in benefit and failure in harm 2 individualise use of low dose pred in RA >65y/o”
Robert B Chao, MD doctorRBC
3 years 1 month ago
CAR T cell therapy for treatment of lupus
Small sample size of 5 pts, but improvement in all pts, 4 achieving SLEDAI =0
Note - cytokine release syndrome in 3 pts.
Excellent overview of CAR T cell therapy and its complexity!
@RheumNow #ACR22 https://t.co/3PP14tVudb
Julian Segan JulianSegan
3 years 1 month ago
MTX increases pegloticase efficacy in MIRROR trial. Similar safety too. Shame the cost of pegloticase is prohibitive in Australia...
@RheumNow #ACR22 #yearinreview
Eric Dein ericdeinmd
3 years 1 month ago
Year in Review
#ACR22
Pegloticase and MTX now FDA approved co-administration for tophaceous gout to prevent anti-drug antibodies
@RheumNow https://t.co/EPtOrjJqLd
Robert B Chao, MD doctorRBC
3 years 1 month ago
Preview of what is sure to be discussed more in detail later..
MIRROR trial of MTX co-administration with pegloticase in treatment of gout.
MTX co-administration improved control of gout, reduced infusion reactions
@RheumNow #ACR22 https://t.co/r0MEq1rkgO
Aurelie Najm AurelieRheumo
3 years 1 month ago
ACR year in review: a summary of latest FDA approvals in spondyloarthritis by C. Langford
#ACRyearinreview #ACR22 @RheumNow https://t.co/u5TyRdQM7L
TheDaoIndex KDAO2011
3 years 1 month ago
Dr. C Langford on #YearinReview: ORAL Surveillance noted NNH=16 in pts w/ASCVD compared to NNH 223 in pts w/o ASCVD. This led to FDA warning on all JAKi; how does not this apply to the new JAKi's? Discussion needed with patients when starting this class of drug #ACR22 @rheumnow https://t.co/XtJVap6yjh
Bella Mehta bella_mehta
3 years 1 month ago
Year in review #ACR22
IVIG received FDA approval for dermatomyositis in 2022!
@RheumNow
Eric Dein ericdeinmd
3 years 1 month ago
Year in Review #ACR22
IVIG received FDA approval for adult dermatomyositis, shows benefit versus placebo
First approved Rx for inflammatory myositis
@RheumNow https://t.co/T6qVTQQdTp
Mike Putman EBRheum
3 years 1 month ago
Good rundown of the PRODERM trial, published @NEJM earlier this year and on my podcast (https://t.co/PzEDiBdJZn) a few eps back
I disagree w/Dr. Langford re:role in therapy. I use IVIG first line for most all pts w/myositis, grateful for the FDA approval!
#ACR22 @RheumNow https://t.co/BfHZm4Kl49
Poster Hall